⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RNXT News
RenovoRx, Inc. Common Stock
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum
globenewswire.com
RNXT
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum
globenewswire.com
RNXT
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting
globenewswire.com
RNXT
RenovoRx Establishes RenovoCath® Medical Advisory Board
globenewswire.com
RNXT
RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer
globenewswire.com
RNXT
RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting
globenewswire.com
RNXT
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors
prnewswire.com
ONCY
RNXT
VSTM
PFE
CATX
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting
globenewswire.com
RNXT
RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center
globenewswire.com
RNXT
The $170B Survival Race: Why Big Pharma is Snapping Up Late-Stage Cancer Tech
globenewswire.com
ONCY
SLS
CELC
RNXT